Skip to main content

tilatamig samrotecan

Generic: Tilatamig Samrotecan

tilatamig samrotecan: 2 clinical trials tracked.

tilatamig samrotecan evidence translation

What we can confirm

2 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about tilatamig samrotecan, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 1 study sponsors
Clinical Trials (2)

A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592

NCT06366451·Early Phase 1
Completed

Primary endpoint: Evaluation of signature scores using Gene Set Variability Analysis within regions injected with microdoses of rilvegostomig, volrustomig, sabestomig, AZD9592, or pembrolizumab as single agents or as AZD9592 drug combinations with the evaluated biologics

Interventionalopen17 enrolledStarted 2024-05Completion 2026-037 sites · United StatesPresage Biosciences

A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors

NCT05647122·Phase 1·AZN
Active, not recruiting

Primary endpoint: Incidence of Adverse Events (AEs)

Interventionalopen167 targetStarted 2022-12Completion 2028-0846 sites · Australia, Canada, China, France…AstraZeneca